Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences ...
Individuals who develop antibodies against the GluN1 subunit of NMDA receptors can develop NMDA receptor encephalitis (NMDARE), which can lead to psychosis, cognitive deficits and movement disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results